Adult patients with severe CRSwNP treated with tezepelumab continued to receive benefit 24 weeks after treatment cessation.

Findings showed treatment with tezepelumab significantly reduced the size of nasal polyps and nasal congestion compared with placebo. The Food and Drug Administration (FDA) has approved Tezspire ® ...

Please provide your email address to receive an email when new articles are posted on . Mean Asthma Control Questionnaire-6 scores fell from 2.6 at baseline to 1.4 at week 52. 47.3% had partially or ...

The FDA has approved Tezspire (tezepelumab-ekko), a biologic therapy by Amgen and AstraZeneca, as an add-on maintenance treatment for patients aged 12 years and older with inadequately controlled ...

On October 17, 2025, Amgen and AstraZeneca announced that the FDA has approved an additional indication for TEZSPIRE (tezepelumab-ekko) for the add-on maintenance treatment of inadequately controlled ...

Female sex is associated with up to 44% increased odds of chronic rhinosinusitis without nasal polyps (CRSsNP), but 37% reduced odds of chronic rhinosinusitis with nasal polyps (CRSwNP), with lower ...

Even in eosinophilic granulomatosis with polyangiitis (EGPA), not all manifestations of eosinophilic inflammation respond equally to anti–interleukin-5 (IL-5) therapy. We report a case of ...

Please provide your email address to receive an email when new articles are posted on . Patients with both chronic rhinosinusitis with nasal polyps and asthma experience greater disease severity and ...